Gamblers, psychics, speculators and coin-flippers: Mark your calendars, one and all, for a date likely to be the most spectacular one-day investment event in the first half of 2007. On May 15, a week and a half from today, years of scientific research, venture investment, hope and prayer will result in an up-or-down vote from federal drug regulators on a prostate-cancer therapy developed by Dendreon (DNDN - Cramer’s Take - Stockpickr - Rating), a small Seattle biotech company. >>> Discuss This Story
